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Synopsis 
Platelets are small anuclear cells that play a central role in haemostasis.  Platelets become activated 
in response to various stimuli triggering release of their granular contents into the surrounding 
milieu.  One of these types of granules, termed dense granules, have been found to contain polyP in 
addition to other inorganic biomolecules, such as serotonin, ADP, ATP, PPi.  Individuals deficient in 
dense granules exhibit bleeding tendencies, emphasising their importance in haemostasis.   Platelet 
polyP is of a relatively defined size, approximately 60-100 phosphate monomers in length.  These 
linear polymers act at various points in the coagulation and fibrinolytic systems thereby modulating 
the haemostatic response.  Due to its highly anionic nature polyP lends itself to being a natural 
activator of the contact system.  The contact system functions in multiple pathways including 
coagulation, fibrinolysis, inflammation and complement.  Activation of the contact system 
accelerates thrombin generation, the terminal enzyme in the coagulation cascade. PolyP also 
modulates factors further downstream in the coagulation cascade to augment thrombin generation.  
The net effect is increased fibrin formation and platelet activation resulting in faster clot formation.  
PolyP is incorporated into the forming clot thereby modifying the structure of the resulting fibrin 
network and its susceptibility to degradation by certain plasminogen activators.  In conclusion, 
release of platelet polyP at the site of injury may facilitate clot formation and augment clot stability 
thereby promoting wound healing. 
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 Polyphosphate (polyP) is a ubiquitous molecule present in all living organisms and is highly 
conserved throughout evolution  [1].  It is a linear unbranched polymer of inorganic phosphate 
residues linked by energy-rich phosphoanhydride bonds, such as those found in ADP, which varies 
considerably in length depending on the organism and tissue of synthesis.  The majority of our 
knowledge of polyP synthesis and regulation is derived from prokaroyotes and unicellular 
eurokaryotes, where a γ-phosphate of ATP is transferred to a growing chain of phosphate residues 
by an enzymatic reaction [1].  PolyP can be degraded through the action of exophosphatases and 
endophosphatases, which remove phosphate resides from either termini or cleave internal 
phosphoanhydride bonds, respectively.  The potential of polyP to function in metabolic processes is 
underscored by its chemical and physical properties, such as its strong anionic nature, its ability to 
form high energy bonds and its capacity to complex with Ca2+ and other divalent cations.  There is a 
wealth of literature on the functions of polyP in prokaryotes and single-cell eukaryotes  [2] where it 
essential for normal physiological processes such as motility, virulence and stress responses [3].  
However, until recently the role of this polymer in mammalian systems was relatively undefined.  In 
2004, Ruiz et al  [4] established distinct similarities between acidocalcisomes in bacteria and the 
dense granules contained within human platelets, as both types of organelles are acidic in 
nature  [5], electron dense, contain high concentrations of divalent cations and are a rich source of 
ADP/ATP as well as inorganic phosphate [6].  Further purification of these dense granules 
(sometimes referred to as delta granules) revealed that they also store high concentrations of polyP.  
This review will focus on the haemostatic functions of platelet-derived polyP that have been 
uncovered in the last decade since its identification in these small anucleate blood cells.  
 
Platelets and polyP 
Platelets are the smallest cell in blood with a diameter of 2-5 µm and circulate at high 
concentrations (~1.5-4.5 x108/ml).   Platelets are crucial to the haemostatic response and provide 
the first point of contact with the damaged endothelium by interacting with collagen and von 
Willebrand factor, thereby forming an initial platelet plug (an event termed primary haemostasis).  
Their role in haemostasis does not end here as they continue to support secondary haemostasis by 
providing a procoagulant surface for assembly of plasma derived coagulation factors and ultimately 
facilitate generation of the clotting enzyme thrombin. They also provide an anchor for fibrin, via the 
integrin receptor αIIbβ3, to support the growing clot and release a host of proteins from their α-
granules and modulators from their dense granules to regulate clot formation, stability and 
degradation.      
 
PolyP is contained at high concentration of around 130 mM within platelet dense granules and is of 
a narrow size range, compared to long-chain microbial polyP, of around 60-100 phosphate 
monomers in length.  The pool of polyP is released into the secretome of platelets following 
activation by such as thrombin, ADP and collagen, alongside other dense granule contents including 
ADP and serotonin  [4, 7].  Secretion of polyP upon platelet stimulation results in release of low 
micromolar concentrations of polyP into the circulation (expressed in terms of phosphate 
monomer).  Once released polyP is likely to have a relatively limited half-life of 1-2 h in plasma 
before it is degraded by phosphatase enzymes [8].   
 
The crucial role of platelets in the haemostatic response and the fact that individuals with defects in 
dense granules exhibit bleeding tendencies [9] prompted our analysis of the functional effects of 
polyP in these processes.  Using synthetic polyP, of approximately the size found in platelets, we 
demonstrated that this polymer can significantly augment coagulation and delay fibrinolysis (Figure 
1A)  [8].  PolyP-mediated acceleration of coagulation occurs at several points in the cascade 
including initiating activation of the contact pathway (Figure 1B)  [8], accelerating thrombin-
mediated activation of factor XI  [10] and enhancing conversion of the procofactor factor V to factor 
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Va  [8].  The effect of polyP on thrombin generation has down-stream repercussions in terms of 
fibrinolysis, where it augments activation of the fibrinolytic modulator, thrombin activatable 
fibrinolysis inhibitor (TAFI).  PolyP also binds to a number of the haemostatic proteins including 
thrombin [11], kallikrein [12], factor XI (FXI)  [10] and factor XII (FXII)  [7, 13].  It also associates with 
fibrinogen [14] which, once cleaved by thrombin to fibrin, provides the main scaffold of the forming 
clot.   These observations led to the hypothesis that polyP operates as a timed switch, to enhance 
repair of an injured region while simultaneously preventing clot breakdown until wound healing 
occurs  [8].  These multifaceted effects of polyP on haemostasis will now be discussed in more detail.     
 
PolyP-mediated effects on the contact pathway 
The contact pathway is composed of four proteins, factor XII (FXII), prekallikrein (PK), factor XI (FXI) 
and high molecular weight kininogen (HK) (Figure 2).  Reciprocal proteolytic activation of FXII and PK 
to their active forms, FXIIa and kallikrein respectively, is stimulated by negatively charged surfaces 
(Figure 2).  FXIIa then cleaves FXI to its activated form, FXIa.  FXI and PK circulate in complex with the 
non-enzymatic cofactor HK, which assembles these proteases onto the activating surface.  Zinc ions 
induce a conformational change in FXII [15-19] and HK [20-22], enhancing surface interactions.   The 
function of FXII in coagulation has been questioned as congenital deficiencies are not associated 
with bleeding in humans [23] or in mice [24, 25].  Advances in defining the pathophysiological 
importance of the contact pathway have been made using FXII-deficient mice, which show normal 
haemostasis and early thrombus formation but a clear defect in thrombus stabilisation [26, 27].  A 
major obstacle in defining the physiological role of this pathway has been the lack of an appropriate 
biological surface capable of initiating contact activation.  However, in the past decade our work [7, 
8, 13] and others [28-30] has identified natural surfaces such as, RNA [28], misfolded proteins [29], 
collagen [30] and, relevant to this review, polyP [7, 8, 13], that all fuel FXII activation.   
FXII has several putative binding sites for anionic surfaces within the fibronectin type II [31-33] and 
type I domains [34].   Cleavage at Arg353-Val354 generates αFXIIa, a disulphide linked two-chain 
protein composed of a heavy chain and light chain.  Further cleavage at Arg334-Val335 generates 
βFXIIa, a proteolytic form that lacks the surface binding domains.  βFXIIa can cleave PK at similar 
rates to αFXIIa but is an inefficient activator of FXI [35].  PolyP binds directly to FXII and can induce 
autoactivation and activation by kallikrein [7], although the exact location of this binding site has not 
been elucidated.  Interestingly, we have shown that polyP, of around the chain length in platelets, 
when bound to FXII can induce activity in the single-chain form of the protease [13].  This FXII-polyP 
complex is functional in cleaving downstream targets of FXII including FXI and kallikiren and is 
efficiently inhibited by the physiological inhibitor C1-inhibitor.  In contrast, longer chain polyP (≥500 
mer) are much more efficient at stimulating FXII activation [36] and drive formation of the cleaved 
two chain αFXIIa form.  These data are consistent with previous observations showing that 
autoactivation of FXII is induced more slowly by low molecular mass polysaccharides, than higher 
molecular mass polysaccharides of 10000 Da and above [31]. The increased level of autoactivation 
observed with these different chain lengths of polymers is rationalised by the increase in available 
binding sites on longer polymers.  Assuming a bond length of P-O as 1.5 Å, we can derive the length 
of polyP70 as approximately 20 nm.  The diameter of FXII is 5-6 nm (Mr = 80 000) based on the 
assumption that the protein molecule is approximately spherical [31]. These approximate 
calculations infer that around four FXII molecules could bind to polyP70 which may account for the 
levels of autoactivation and activity observed  [13].  These data provide novel insights into the 
subtleties that regulate FXII autoactivation by naturally occurring anionic surfaces and suggest that 
when FXII is in association with different ‘cofactor surfaces’ it may have different functional activity. 
 
Platelet-derived polyP has been identified as an efficient stimulator of autoactivation and thrombin-
mediated activation of FXI [10]. PolyP is known to bind to thrombin via exosite II [10, 11] and factor 
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XI via the anion binding sites [7, 10, 37] therefore it is likely that polyP elicits it functions via a 
template mechanism.  In this model proteases bind to the surface via distinct exosites thereby 
lowering the dissociation constant and enhancing interaction with their target zymogens.  This is a 
familiar mechanism in haemostasis in terms of heparin-enhanced inhibition of thrombin by 
antithrombin [38] and fibrin-stimulated activation of plasminogen by tissue plasminogen activator 
(tPA)  [39].  The study by Choi et al [10] suggests that within the plasma milieu the presence of both 
polyP and thrombin could potentiate thrombin generation via autoactivation of FXI or enhanced 
thrombin-mediated cleavage of FXI.  Interestingly, binding of polyP to FXI also accelerates 
downstream factor V activation, acting at a further point to accelerate local thrombin 
generation [40].  These observations could help to explain the mild bleeding phenotype associated 
with FXI deficiency (Haemophilia C), which is absent in FXII deficient individuals.  
Since the discovery that the contact pathway is dispensable for haemostasis but functions in 
thrombosis it has been pinpointed as a safe target for antithrombotic drugs that can inhibit clot 
formation with minimal bleeding complications [41].  A recent study has also elegantly 
demonstrated that antisense inhibition of FXI decreased the degree of deep vein thrombosis after 
knee arthroplasty, defining a key role for FXIa in mediating thrombus formation in vivo [42].  The 
importance of the contact pathway in fibrin deposition has recently been reported in a flow-based 
model using human blood [43].  The authors show that inhibition of FXIIa-mediated and thrombin-
mediated FXI activation reduces fibrin formation while having no direct impact on platelet 
deposition [43].  Interestingly, inclusion of a polyP binding protein modulated fibrin deposition at 
low TF concentrations suggesting a contact system-independent effect on the extrinsic pathway [43].  
In collaboration with the Renne laboratory and others [7] we have shown that intravenous 
administration of polyP into mice results in fatal pulmonary embolism, however mice deficient in 
FXII or wild-type mice treated with a FXII inhibitor survive this challenge, illustrating a clear role for 
polyP in modulating FXII activation in vivo [7].  Recent observations have shown the polyP-FXII 
pathway drives thrombosis in prostate cancer [44].   Prostate cancer cells and the exosome they 
release (prostasomes) expose long-chain polyP on their surface that triggers FXII activation and 
downstream clotting in prostate cancer patient plasma and thrombosis in mice [44].  Inhibition of 
the polyP-FXII pathway reduces thrombosis in mice with no bleeding complications identifying this 
pathway as a novel therapeutic target for anticoagulant drug development for the treatment of 
prostate cancer-induced thrombosis.  Indeed, studies are already underway to identify polyP 
inhibitors and have been shown to reduce venous and arterial thrombosis in vivo [45].  Travers et 
al [46] demonstrate that non-toxic dendritic polymer based compounds were efficient at modulating 
polyP induced coagulation in vitro and in vivo.  This highlights the possibly of future drugs based on 
similar technology that could be used to treat various types of thromboembolic complications.        
 
PolyP enhances thrombin generation 
PolyP significantly augments thrombin generation [8] suggesting it has a direct effect on the 
common pathway (Figure 2).  Factor V is the circulating protein procofactor for factor Va, which is 
essential for prothrombin activation by factor Xa. Our initial studies into polyP’s function in 
coagulation revealed that it accelerates conversion of factor V to factor Va by both factor Xa and 
thrombin [8], of which the latter is considered to be the principal activator in vivo [47].  Enhanced 
activation of factor V occurs readily with polyP of the size found in platelets [36].  Platelet α-granules 
store a proteolytically modified form of factor Va which is more susceptible to activation  [48, 49].  
Activated platelets provide a surface for binding of the coagulation factors, specifically factor X, 
prothrombin and factor V.  Taken together this suggests that concomitant release of platelet polyP 
and platelet factor V is an important route for augmenting local thrombin generation on the surface 
of activated platelets.  
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The amplified conversion of factor V to factor Va in the presence of polyP has intriguing downstream 
consequences in terms of regulation of coagulation.  TFPI is the primary inhibitor of tissue factor 
driven coagulation, acting at several key points to regulate the pathway.  One of the most important 
points of interception is inhibition of factor Xa before it dissociates from the TF-FVIIa complex [50].  
Interestingly, factor Xa is protected from inhibition by TFPI when in complex with its cofactor factor 
Va, particularly in the presence of prothrombin [51].  We found that addition of platelet releasates 
attenuated TFPI function in a polyP-dependent manner [8].  Therefore not only does polyP 
accelerate formation of activated clotting factors it also interferes with the ability of endogenous 
inhibitors to modulate coagulation.   
 
PolyP modulates fibrin formation and stability 
Thrombin is responsible for cleaving circulating fibrinogen to fibrin and is actively incorporated into 
the growing fibrin network.  Thrombin also activates factor XIII, a transglutaminase enzyme whose 
function is to cross-link fibrin and inhibitors, specifically α2AP, into thrombi to stabilise them against 
mechanical  [52, 53] and fibrinolytic degradation [54], respectively.  PolyP is known to bind to 
fibrin [14] and is incorporated into the clot modifying the structure of the resulting fibrin 
network [14, 55].  We observed that fibrin formed in the presence of polyP was extremely 
heterogeneous in nature, being composed of small knotted regions interspersed by large pores 
(Figure 3) [14].  Intriguingly, polyP is located in the centre of these knotted areas (unpublished 
observations Whyte CS & Mutch NJ), as if it functions as a nucleus for fibrin formation.  Fibrinolysis is 
the enzymatic process by which fibrin is degraded.  Plasmin, the central enzyme in fibrinolysis, is 
formed by activation of the zymogen plasminogen by a plasminogen activator, namely tissue 
plasminogen activator (tPA) and urokinase (uPA) (Figure 2).  Both tPA and plasminogen bind avidly to 
C-terminal lysine residues on the fibrin surface and intriguingly fibrin acts as a cofactor in its own 
destruction.  A key consequence of the altered fibrin structure induced by polyP is attenuation of 
tPA-mediated fibrinolysis.  This is in part mediated by the modified fibrin network, but perhaps more 
importantly because polyP tempers the binding of the fibrinolytic proteins plasminogen and tPA to 
fibrin (Figure 3B).  The exact mechanism is not yet defined, but suggest that deficient binding arises 
from obstruction of the C-terminal lysine residues, particularly as these effects are more pronounced 
following plasmin hydrolysis of fibrin which exposes further C-terminal lysine binding sites (Figure 
3B) [14].    
 
TAFI is a procarboxypeptidase that is activated to the enzyme TAFIa via thrombin [56] and 
plasmin [57].  TAFIa modulates fibrinolysis by cleaving the C-terminal lysine residues from fibrin 
attenuating binding of plasminogen and tPA and thereby reducing plasmin generation.  By enhancing 
thrombin generation via the multiple mechanisms described  [7, 8, 10, 40] polyP increases thrombin-
mediated TAFI activation and subsequently down-regulates fibrinolysis (Figure 2).  These 
observations indicate that incorporation of polyP into forming clots stabilises the fibrin network by 
different mechanisms to prevent premature degradation of the clot but in pathological situations 
this may allow clots to persist within the vasculature.       
 
Conclusions and future perspectives 
The work discussed in this review illustrates that platelet polyP modulates haemostasis at 
several distinct points in the cascade.  It is fascinating that a simple molecule like polyP has 
the capacity to mediate these crucial physiological processes.  Several of the procoagulant 
effects of polyP are mediated by its anionic charge and are consistent with a template 
mechanism  [10, 11, 36] and/or allosteric modulation of proteins  [11, 13].  However, many 
of these mechanisms are still relatively undetermined and will undoubtedly prove to be an 
area of important research in future years.  While polyP of the size found in platelets is a 
fairly modest activator of FXII the fact that both FXII [58] and polyP [14, 55] are localised on 
fibrin suggests that it may have site specific pathobiological importance.  The role of polyP is 
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particularly relevant when considering bacterial induced infection, such as sepsis, as 
bacteria contain high concentrations of long-chain polyP, which are potent stimulators of 
FXII activation [36].  It is interesting to speculate that compounds that target polyP may 
provide important new strategies for treating thrombotic complications without the 
bleeding side-effects that are associated with current antithrombotic drugs.  The 
evolutionary conservation of polyP emphasises its biological importance throughout the 
animal kingdom.  The growing body of reports, however, accentuate the current lack of 
knowledge on its synthesis and regulation in mammalian cells and underscores a 
requirement to identify the enzymes responsible for its synthesis and metabolism in vivo.     
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Legends 
Figure 1:  PolyP enhances coagulation and delays fibrinolysis in human plasma.  (A) Combined 
clotting/fibrinolysis assays were performed in human plasma by adding 75 μM polyP75 3 min before 
recalcifying with Ca2+ in the presence of uPA. Clot formation was monitored as an increase in 
absorbance over time and subsequent clot lysis as a decrease.   PolyP dramatically accelerated the 
clot formation time in human plasma from around 25 min to < 5 min.  Time to 50% clot lysis was 
delayed from 40 min to 80 min in the presence of polyP.  (B) Clotting assays were performed by 
preincubating plasma for 2 min with 0 or 75 μM polyP75 before recalcification with Ca2+. The first two 
bars on the left show that addition of polyP to pooled normal plasma (PNP) dramatically shortened 
the clotting time, whereas the next two bars show that addition of polyP to factor XII-deficient 
plasma (XII) did not. The two bars on the right show mixing experiments with normal or factor XII-
deficient plasma in which polyP75 (75 μM) was first preincubated for 2 min with one plasma before 
addition of an equal amount of the other plasma, followed immediately by the addition of Ca2+ to 
initiate clotting. PolyP dramatically shortened the clotting time only when preincubated with normal 
plasma, not with factor XII-deficient plasma, even though the final plasma mixtures were 
identical [8].  
 
Figure 2: PolyP intercepts in the coagulation and fibrinolytic pathways at several points.  
Coagulation can be initated by two pathways; the extrinsic pathway comprised of tissue factor (TF) 
and factor VII (VII) or the contact pathway via reciprocal activation of factor XII (XII) and prekallikrein 
(PK) which associate with negatively charged surfaces via high molecular weight kininogen (HK). 
Generation of factor XIIa (XIIa) cleaves downstream factor XI (XI) to factor XIa (XIa) which feed into 
the intrinsic pathway comprised of factor VIII (VIII) and factor IX (IX).  Both pathways converge at the 
common pathway composed of the prothrombinase complex of factor Va (Va), factor Xa (Xa) and 
prothrombin (PT) ultimately generating thrombin.  Thrombin cleaves fibrinogen to fibrin and and 
activates the transglutaminase factor XIIIa (XIIIa) generating a cross-linked clot.  Cross-linked fibrin is 
degraded to D-dimer (which can be cleared from the circulation) via the fibrinolytic cascade in which 
plasmin is generated from plasminogen by tissue plasminogen activator (tPA) or urokinase (uPA).  
The system is under the control of several inhibitors of which only two are shown; tissue factor 
pathway inhibitor (TFPI) and activated thrombin activatable fibrinolysis inhibitor (TAFIa).  PolyP 
enhances coagulation at several points in the cascade (shown in orange) including; 1. Stimulating 
activation of the contact pathway [7, 8, 13, 36] 2. Amplifying thrombin-mediated activation of factor 
XI  [10] and 3. Augmenting conversion of the procofactor factor V to factor Va  [8, 36].  By enhancing 
factor Va generation polyP indirectly interferes with the function of TFPI.  The effect of polyP on 
thrombin generation has down-stream repercussions in terms of fibrinolysis, where it augments 
activation of TAFI thereby down-regulating fibrinolysis.  PolyP (shown in orange) also binds to a 
number of the haemostatic proteins including thrombin [11], kallikrein [12], XI  [10] and XII  [7, 13] 
and fibrin(ogen). 
Figure 3:  PolyP alters fibrin ultrastructure and down-regulates binding of fibrinolytic proteins to 
fibrin. (A) Fibrin clots were prepared by incubating fibrinogen with thrombin and Ca2+ in the absence 
and the presence of polyP65. Fibrin clots analysed by confocal microscopy (top panel) and by 
scanning electron microscopy (bottom panel). Fibrin formed in the presence of polyP is very 
heterogeneous and is composed of knotted regions interspersed by large pores. (B) Fibrinogen was 
captured on the surface of a Biacore chip and converted to fibrin by thrombin in the absence and 
presence of polyP65. Top panel: binding of 125 nM (black), 250 nM (orange), 500 nM (blue), and 1000 
nM (green) plasminogen was analysed (dashed lines). The surface was then treated with plasmin and 
binding of plasminogen, at the concentrations described above, was repeated (solid lines). Bottom 
panel: As described for top panel with 31.25nM (black), 62.5nM (orange), 125nM (blue), and 250nM 
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(green) tPA instead of plasminogen.  PolyP down-regulated binding of plasminogen and tPA 
especially after plasmin treatment of fibrin. [14]       
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